{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:54:40Z","timestamp":1772153680956,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH intramural research programs of the NIAID and the NCI"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","cgfr.co.uk","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.cytogfr.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T13:45:44Z","timestamp":1458049544000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Monocyte and interferon based therapy for the treatment of ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Daniel S.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana T.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn C.","family":"Zoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2016.02.006_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 6","key":"10.1016\/j.cytogfr.2016.02.006_bib0010","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/cimm.1996.0301","article-title":"HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2","volume":"174","author":"Kooi","year":"1996","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0020","first-page":"263","article-title":"Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion","volume":"2","author":"Dadmarz","year":"1996","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-1759(94)90084-1","article-title":"Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy","volume":"167","author":"Freedman","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000058060","article-title":"Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer","volume":"51","author":"Santin","year":"2001","journal-title":"Gynecol. Obstet. Invest."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0050","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0060","doi-asserted-by":"crossref","first-page":"191832","DOI":"10.1155\/2015\/191832","article-title":"Immunotherapy of ovarian cancer: the role of checkpoint inhibitors","volume":"2015","author":"De Felice","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0065","article-title":"Avelumab. An anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial (MSB0010718C)","volume":"33","author":"Gordon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0070","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/1097-0142(19890901)64:5<1029::AID-CNCR2820640511>3.0.CO;2-#","article-title":"Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer","volume":"64","author":"Bezwoda","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0080","first-page":"437","article-title":"Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer","volume":"15","author":"Ferrari","year":"1994","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0085","first-page":"69","article-title":"Alpha 2b interferon (IFN) by intraperitoneal administration via temporary catheter in ovarian cancer. Preliminary data","volume":"12","author":"Iaffaioli","year":"1991","journal-title":"Eur J. Gynaecol. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0090","first-page":"5853","article-title":"Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity","volume":"48","author":"Lichtenstein","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/gyno.1995.0020","article-title":"A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study","volume":"59","author":"Moore","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0100","first-page":"1641","article-title":"Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study","volume":"11","author":"Repetto","year":"1991","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0105","first-page":"98","article-title":"Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration","volume":"19","author":"Schuller","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0110","first-page":"7318","article-title":"Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells","volume":"50","author":"Allavena","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ijc.2910510109","article-title":"Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy","volume":"51","author":"Colombo","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1988.6.4.689","article-title":"A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma","volume":"6","author":"D\u2019Acquisto","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0125","first-page":"6643","article-title":"Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer","volume":"51","author":"Malik","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.1996.14.2.343","article-title":"Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy","volume":"14","author":"Pujade-Lauraine","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0135","first-page":"6100","article-title":"Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis","volume":"47","author":"Stevenson","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jlb.64.4.419","article-title":"Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives","volume":"64","author":"Andreesen","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4049\/jimmunol.105.1.48","article-title":"Inhibition of target cell proliferation by supernatants from cultures of human peripheral lymphocytes","volume":"105","author":"Green","year":"1970","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","article-title":"Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial","volume":"16","author":"Freedman","year":"1994","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1200\/JCO.1991.9.7.1251","article-title":"study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis","volume":"9","author":"Faradji","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/039139889101400511","article-title":"Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients","volume":"14","author":"Faradji","year":"1991","journal-title":"Int. J. Artif. Organs"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0022-1759(94)90033-7","article-title":"Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients","volume":"174","author":"Faradji","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0170","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.1986.4.11.1677","article-title":"study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients","volume":"4","author":"Kurzrock","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0175","first-page":"234","article-title":"Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma","volume":"7","author":"Quesada","year":"1988","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0180","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0190","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0042-6822(62)90123-X","article-title":"Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells","volume":"17","author":"Paucker","year":"1962","journal-title":"Virology"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/jnci\/55.5.1233","article-title":"Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity","volume":"55","author":"Salvin","year":"1975","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jir.2012.0167","article-title":"Immunomodulatory effects of interferons in malignancies","volume":"33","author":"Bekisz","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/jir.1998.18.17","article-title":"Orally administered IFN-alpha acts alone and in synergistic combination with intraperitoneally administered IFN-gamma to exert an antitumor effect against B16 melanoma in mice","volume":"18","author":"Fleischmann","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0210","series-title":"The Interferon System","author":"IIWES","year":"1979"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0215","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1172\/JCI16603","article-title":"The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse","volume":"112","author":"Lesinski","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0225","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/bjc.2015.459","article-title":"A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer","volume":"113","author":"Koti","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0230","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.272.5262.719","article-title":"Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1\/CIP1 mediated by STAT1","volume":"272","author":"Chin","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0235","doi-asserted-by":"crossref","first-page":"16448","DOI":"10.1073\/pnas.0607830103","article-title":"RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins","volume":"103","author":"Xiao","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0240","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2002-10-3149","article-title":"Ser727\/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0\/G1 arrest of U-937 cells","volume":"102","author":"Dimberg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/107999002753452647","article-title":"IRF-1 as a negative regulator of cell proliferation","volume":"22","author":"Romeo","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0250","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/viro.1997.8494","article-title":"The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases","volume":"231","author":"Lee","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0255","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1038\/sj.onc.1203710","article-title":"The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors","volume":"19","author":"Gil","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0260","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jir.2010.0153","article-title":"Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro","volume":"31","author":"Baron","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jir.2006.0083","article-title":"Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro","volume":"27","author":"Baron","year":"2007","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jir.2014.0057","article-title":"Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin","volume":"35","author":"Johnson","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0275","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00262-011-1152-x","article-title":"Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors","volume":"61","author":"Nakashima","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0280","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0285","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0290","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2007.02.001","article-title":"Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes","volume":"19","author":"Bui","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0295","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0300","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1084\/jem.147.5.1314","article-title":"Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis","volume":"147","author":"Trinchieri","year":"1978","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0305","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.4049\/jimmunol.165.7.3571","article-title":"Distinct requirements for IFNs and STAT1 in NK cell function","volume":"165","author":"Lee","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0310","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/jir.1984.4.265","article-title":"Requirement for IFN gamma in potentiation of interferon\u2019s antiviral and anticellular activities: identity of mouse and human systems","volume":"4","author":"Fleischmann","year":"1984","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0315","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fimmu.2015.00423","article-title":"Blood monocytes and their subsets: established features and open questions","volume":"6","author":"Ziegler-Heitbrock","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.immuni.2010.08.012","article-title":"Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors","volume":"33","author":"Cros","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0325","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1182\/blood-2009-07-235028","article-title":"Comparison of gene expression profiles between human and mouse monocyte subsets","volume":"115","author":"Ingersoll","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/newbio232076a0","article-title":"Endotoxin and double stranded RNA render macrophages cytotoxic","volume":"232","author":"Alexander","year":"1971","journal-title":"Nat. N. Biol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0335","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(71)90222-4","article-title":"Role of activated macrophages and antibody in inhibition and enhancement of tumour growth in rats","volume":"2","author":"Keller","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0340","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/newbio235048a0","article-title":"Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance","volume":"235","author":"Hibbs","year":"1972","journal-title":"Nat. N. Biol."},{"issue":"Suppl. 1","key":"10.1016\/j.cytogfr.2016.02.006_bib0345","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/338005","article-title":"Infection and nitric oxide","volume":"185","author":"Hibbs","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0350","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0355","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: phenotypical vs: functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0360","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1189\/jlb.0406249","article-title":"Biochemical and functional characterization of three activated macrophage populations","volume":"80","author":"Edwards","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0365","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0370","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.it.2011.12.001","article-title":"Differential macrophage programming in the tumor microenvironment","volume":"33","author":"Ruffell","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0375","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.bbamcr.2012.05.031","article-title":"Apoptosis-inducing factor (AIF) is targeted in IFN-alpha2a-induced Bid-mediated apoptosis through Bak activation in ovarian cancer cells","volume":"1823","author":"Miyake","year":"2012","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-065X.2008.00614.x","article-title":"The impact of T-cell immunity on ovarian cancer outcomes","volume":"222","author":"Nelson","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0385","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","DOI":"10.1038\/nature10166"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0390","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma","author":"Darb-Esfahani","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0395","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0400","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0405","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer","volume":"49","author":"Droeser","year":"2013","journal-title":"Eur. J. Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab. Invest."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0415","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0420","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0425","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V97.6.1809","article-title":"B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function","volume":"97","author":"Tamura","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0430","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2004.06.013","article-title":"Interferon-\u03b2 enhances monocyte and dendritic cell expression of B7-H1 (PD-L1) a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis","volume":"155","author":"Schreiner","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cytogfr.2016.02.006_bib0435","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clim.2008.05.009","article-title":"PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes","volume":"129","author":"Boasso","year":"2008","journal-title":"Clin. Immunol. (Orlando, Fla)"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610116300302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610116300302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T02:53:20Z","timestamp":1692240800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610116300302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":87,"alternative-id":["S1359610116300302"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2016.02.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monocyte and interferon based therapy for the treatment of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}